NEW YORK, Jan. 7 (GenomeWeb News) - Burrill & Company, a San Francisco-based life sciences merc
"We're looking at tools and technologies that will move us further and faster towards personalized and predictive medicine," Steven Burrill, CEO of the company, told GenomeWeb News today. "Biomarkers would be a real important part of that, as well as technology that will allow you to walk into a lab and get your genome sequenced."
According to Burrill, the new fund, called the Burrill Life Sciences Capital Fund III, will go to 20 to 25 companies worldwide at various stages of development, from seed and early stage to mezzanine levels. Each company will receive about $20 million in funding.
Burrill & Company currently has $500 million under management. BLSCF III is Burrill's third generation of venture funds. First generation funds, established in 1998, include a human health-care focused fund called the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and the Burrill Nutraceuticals Capital Fund. Second generation funds, established in 2002, include the $211 million Burrill Life Sciences Capital fund.